Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies

The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib has been approved for years as a first-line therapy for patients harboring EGFR-sensitizing mutations. With the promising implementation of immunotherapeutic strategies for the treatment of lung cancer, there is a gr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cell Death Dis
Huvudupphovsmän: Dominguez, Charli, Tsang, Kwong-Yok, Palena, Claudia
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2016
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5059888/
https://ncbi.nlm.nih.gov/pubmed/27685624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2016.297
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk